Background. We evaluated the association of respiratory complications and amiodarone use in patients with atrial fibrillation (AF) after major lung resection.
Conclusions. Atrial fibrillation that occurs without an antecedent respiratory complication in patients after major lung resection results in longer hospital stay but not increased mortality or respiratory morbidity. Using amiodarone to treat atrial fibrillation after major lung resection is not associated with an increased incidence of respiratory complications.
(Ann Thorac Surg 2014;98:1199-206) Ó 2014 by The Society of Thoracic Surgeons S upraventricular arrhythmias including atrial fibrillation, atrial flutter, and supraventricular tachycardia occur in up to 25% of patients after lung resections, most often on the second postoperative day [1] [2] [3] [4] [5] [6] [7] [8] . Risk factors for arrhythmia include more extensive resections such as bilobectomy and pneumonectomy, intrapericardial and extrapleural pneumonectomy, right-sided procedures, age over 60 years, male sex, patient race other than black, stage II or higher lung cancers, history of congestive heart failure, history of previous arrhythmia, preoperative heart rate greater than or equal to 72 beats per minute, history of peripheral vascular disease, intraoperative transfusions, and the occurrence of another complication [4] [5] [6] [8] [9] [10] [11] . The precise cause of arrhythmias after anatomic lung resections is unclear and likely multifactorial, involving hilar dissection, autonomic denervation, stress-mediated neurohumoral mechanisms, inflammatory mediators, and atrial size [5, 8, [12] [13] [14] . Postoperative arrhythmias are associated with a prolonged hospital stay, higher hospital costs, and increased mortality, as well as an increased occurrence of other complications [4, 7, 9, 10, 15, 16] .
Amiodarone is an antiarrhythmic agent commonly used to treat atrial fibrillation. Pulmonary toxicity, including chronic interstitial pneumonitis, organizing pneumonia, and adult respiratory distress syndrome, occurs in approximately 5% of patients who receive amiodarone, with older age and higher amiodarone doses being risk factors [17, 18] . The safety of using amiodarone after lung resection in general and pneumonectomy in particular was questioned by a prospective, randomized single-center study that was evaluating the prophylactic use of amiodarone after lung resection and was terminated early when 3 of 11 patients who were given amiodarone after right pneumonectomy developed adult respiratory disease syndrome [19] . Despite this risk of pulmonary toxicity, amiodarone has been shown to be effective when given prophylactically for the prevention of atrial fibrillation after lung resection as well as to be safe when given to treat atrial fibrillation after lung resection [20] [21] [22] [23] [24] . However, these studies were all relatively small, with the largest study involving 65 patients who were given amiodarone after lung resection. The purpose of this study is to examine whether amiodarone administration after major lung resection is independently associated with pulmonary complications in a larger cohort of patients. The study tested the hypothesis that amiodarone, when used to treat atrial fibrillation that occurs after lobectomy, bilobectomy, or pneumonectomy, is independently associated with increased risk of pulmonary complications.
Patients and Methods
Local Institutional Review Board approval was granted for this study, including waiver of the need for patient consent. All patients treated with lobectomy, bilobectomy, or pneumonectomy from October 28, 2003 through October 1, 2010 were identified both by review of a prospectively maintained database of thoracic surgery patients at Duke University as well as by query of Duke University Health System electronic records using specific procedure codes associated with lobectomy, bilobectomy, and pneumonectomy. Patients who underwent extrapleural pneumonectomy for malignant mesothelioma were excluded from the analysis, as were patients who had concomitant chest wall or diaphragm resection or who were chronically in atrial fibrillation prior to surgery. Retrospective review of the institutional, prospective thoracic surgery database documented demographics, preoperative functional status, use of induction therapy, smoking history, significant comorbidities, histology and disease stage, intraoperative details, and postoperative course. Chart review was utilized as necessary to complete data collection; individual operative notes and surgical pathology reports to confirm that patients underwent anatomic lobectomy, bilobectomy, or pneumonectomy.
Postoperative amiodarone use was ascertained using the Duke University Health System DEDUCE [Duke Enterprise Data Unified Content Explorer] tool that allows query of medication orders. The earliest data available for medications through this tool was October 28, 2003. The study therefore considered patients who had surgery between October 28, 2003 and October 1, 2010. Within this study time frame patients were not routinely given any prophylactic agents for atrial fibrillation. Postoperatively, all patients had continuous telemetry monitoring. Atrial fibrillation suspected by telemetry was confirmed with 12-lead electrocardiograms. Atrial fibrillation treatment was provider dependent, and typically would involve beta-blockers, calcium-channel blockers, or amiodarone. The standard amiodarone regimen was initial intravenous bolus of 150 mg followed by continuous intravenous administration at 1 mg/minute for 6 hours and then 0.5 mg/minute for 18 hours, after which patients were converted to an oral daily dose of 200 mg. Duration of treatment was at the discretion of the surgeon, but the medication was usually discontinued no later than after 30 days of treatment if the patients were in sinus rhythm on follow-up. Patients who were taking rate-controlling agents such as beta-blockers and calcium-channel blockers before surgery had these medications routinely continued in the perioperative period. Anticoagulation was not typically used.
Outcomes of interest included any postoperative event prolonging or otherwise altering the postoperative course as well as operative deaths, which were defined as deaths that occurred within 30 days of the operation or prior to discharge. Deaths were captured both by chart review and use of the Social Security Death Index Database. The definitions of postoperative events were based on the Society of Thoracic Surgeons General Thoracic Surgery Database, and were clearly stated prior to data collection and assessed blinded to exposure variables [25] . Respiratory morbidity was defined as the occurrence of at least 1 of the following postoperative events: atelectasis requiring bronchoscopy; pneumonia; reintubation; and tracheostomy. These pulmonary complications were considered together because they all could be expected to occur more often in the setting of amiodarone-induced lung parenchymal injury.
The cohort used for the amiodarone risk analysis was assembled as follows (Fig 1) . The patients were initially divided into 2 groups according to whether or not they had postoperative atrial fibrillation; baseline characteristics, operative details, and postoperative outcomes between these 2 groups were evaluated with univariate analysis. In the cohort of patients who had postoperative atrial fibrillation, patients who had a respiratory complication that occurred before the onset of atrial fibrillation were excluded from the subsequent analysis that evaluated the risk of amiodarone use. This exclusion was done because the main objective of the study was to assess the risk of having a respiratory complication after amiodarone use. In the cohort of interest, baseline characteristics, operative details, and outcomes between patients who did and did not receive amiodarone were compared. In addition, these variables were also compared between patients who did or did not receive amiodarone in a potentially higher risk subgroup of patients with poor pulmonary function, defined as either preoperative forced expiratory volume in 1 second (FEV 1 ) or preoperative diffusion capacity of the lung to carbon monoxide (DLCO) less than 60% predicted.
Multivariable analysis of the patients who had atrial fibrillation that did not occur after a respiratory complication was performed to assess whether amiodarone exposure is an independent risk factor when other known risk factors for pulmonary complications are considered. The number of risk factors to consider in the model in addition to the risk factor of interest (amiodarone use) was chosen after review of the number of outcome events. The risk factors chosen for analysis were those previously shown to be strongly associated with respiratory complications in other studies; age, extent of resection (lobectomy, bilobectomy, sleeve lobectomy, pneumonectomy), and preoperative percent predicted DLCO. The model was created using stepwise selection with p values of 0.1 both for entry into and to stay in the model. Because amiodarone exposure was the main predictor of interest, its inclusion was forced into the model.
The Mann-Whitney-Wilcoxon test was used to compare continuous variables, and conventional c 2 or Fisher exact test was used to compare categoric variables. A nominal 2-sided p value of less than 0.05 was considered significant. Continuous data were presented as mean AE standard deviation or median (25th, 75th percentile). The SAS V9.2 or higher (SAS Institute, Cary, NC) was used for statistical analyses.
Results
Lobectomy, bilobectomy, and pneumonectomy were performed in 1,412 patients overall during the study period. Table 1 shows the baseline characteristics, comorbid conditions pathologic cancer stage, and resection details for patients stratified by whether or not they developed atrial fibrillation. Two lobes were resected in 72 of the lobar resections; 31 of these procedures were done by video-assisted thoracic surgery and 41 were done by thoracotomy. Of the lobar resections, 69 were sleeve resections. Table 2 shows postoperative events and outcomes. Overall mortality was 3.2% (46 patients) and overall morbidity was 40% (558 patients).
Atrial fibrillation was the most common complication, and occurred in 232 patients (16%). As shown in Table 1 , patients who developed atrial fibrillation were older, had lower percent predicted FEV 1 and DLCO, and more often had hypertension, coronary artery disease, and thoracotomy as the surgical approach for lobar resections when compared with patients who did not have atrial fibrillation. The occurrence of atrial fibrillation was associated with longer hospital stay and significantly increased mortality. Atrial fibrillation was also associated with an increased incidence of other complications, including postoperative transfusion, any respiratory complication, prolonged air leak, need for an enteral feeding tube, new renal insufficiency, and reoperation for bleeding ( Table 2) .
Respiratory complications also occurred in 22% (n ¼ 51) of the 232 patients who had atrial fibrillation. Overall outcomes were significantly different depending on the timing of atrial fibrillation and respiratory complications. Atrial fibrillation developed after a respiratory complication had already occurred in 31 of these patients (13%). These 31 patients had a perioperative mortality of 32% (10 patients) and a median hospital stay of 14 days (9 to 31). The remaining 201 patients who had atrial fibrillation had a perioperative mortality of 3.0% (n ¼ 6) and median hospital stay of 5 days (4 to 7), both of which were significantly less than those of the patients who developed atrial fibrillation after a respiratory complication (p < 0.0001 and p 0.0001, respectively). These 201 patients who had atrial fibrillation that did not occur after a respiratory complication had similar perioperative mortality Of the 201 patients who had atrial fibrillation that did not occur after a respiratory complication, 10% (n ¼ 20) had a subsequent respiratory complication that occurred after initially having atrial fibrillation. Amiodarone was used in 101 (50%) of these 201 patients; preoperative medications in these 101 patients included a betablocker in 33 (33%) and a calcium-channel blocker in 2 (2%). Amiodarone was administered in the hospital only in 35 patients (35%), while 66 patients (65%) were discharged on an oral short-term regimen of amiodarone. Of the 101 patients who were given amiodarone, other medications that were given prior to amiodarone administration and failed to adequately control postoperative atrial fibrillation included intravenous diltiazem (n ¼ 9, 9%) and an intravenous beta-blocker (n ¼ 67, 66%). Of the patients who were given amiodarone, 97% (98 of 101) were in sinus rhythm at the time of discharge and 90 of 92 (98%) patients who had rhythm recorded at the first post-discharge follow-up visit were in sinus rhythm. There were 19 patients treated with amiodarone who had a readmission after their initial hospitalization, two of whom were admitted for management of recurrent atrial arrhythmias. The other reasons for readmission were management of dyspnea (n ¼ 3), pneumonia (n ¼ 3), wound complication (n ¼ 3), pulmonary embolus (n ¼ 2), pneumothorax (n ¼ 2), pulmonary secretion management (n ¼ 1), and pleural effusion (n ¼ 3).
Patients who received amiodarone had similar ages, preoperative pulmonary function, extent of resection, and operative approach when compared with patients who were not given amiodarone, though patients who received amiodarone were more likely to have had previous thoracic surgery (Table 3) . Outcomes in terms of 30-day mortality, hospital stay, and both aggregated and individual respiratory complications were not significantly different between the patients who were given and not given amiodarone. In univariate analysis, amiodarone use was not associated with a significant difference in the incidence of subsequent respiratory complications (12% [12 of 101 patients who received amiodarone] vs 8% [8 of 100 patients who were not given amiodarone], p ¼ 0.5). In a multivariate model that included amiodarone use as well as other known risk factors for respiratory complications, percent predicted DLCO was the only statistically significant predictor of respiratory complications (Table 4 ). In subgroup analysis of patients with poor pulmonary function who had atrial fibrillation after lobectomy, bilobectomy, or pneumonectomy, amiodarone use was also not significantly associated with perioperative mortality or respiratory morbidity (Table 5) .
Comment
In this study we found that atrial fibrillation was the most common postoperative complication that occurred in a cohort of patients who underwent lobectomy, bilobectomy, or pneumonectomy. The occurrence of atrial fibrillation was associated with significantly increased mortality, longer hospital stay, and an increased incidence of other complications, including respiratory complications. Amiodarone was not associated with an increased risk of respiratory complications when used to treat atrial fibrillation in patients who had not already suffered a respiratory complication. Despite the efficacy of amiodarone in treating atrial fibrillation, some surgeons have been reluctant to use amiodarone after major lung resection due to both its known association with pulmonary toxicity as well as previous reports that have suggested amiodarone use increases the risk of pulmonary complications after lung resection [19] . This study, which includes 101 patients treated with amiodarone after major lung resection, suggests that amiodarone is indeed safe to use in this setting. The finding that patients with atrial fibrillation had significantly worse mortality than patients who did not have atrial fibrillation is similar to what has been shown by previous studies [8] . However, more detailed analysis in our study shows there are 2 different subsets of patients in regard to the association of atrial fibrillation and other outcomes. Patients who develop atrial fibrillation after already having had a respiratory complication had significantly increased mortality and hospital stays when compared with patients who develop atrial fibrillation without already having had a respiratory complication. The impact on ultimate outcomes of developing atrial fibrillation after another serious complication is unclear. However, patients who develop atrial fibrillation without already having had a respiratory complication have similar mortality but longer hospital stays compared with patients who do not have postoperative atrial fibrillation. Therefore, strategies that prevent or more quickly treat atrial fibrillation after major lung resection have the potential to reduce costs by reducing hospital stay.
The main strength of this study is that the sample size of patients treated with amiodarone is larger than other published studies that have investigated the use of amiodarone after lung resection. This sample size allowed creation of a multivariable model of complications using previously published prognostic factors in addition to amiodarone use. A limitation of this proposed study is its at least partial reliance on an administrative database regarding amiodarone use. Amiodarone may have been ordered but not given to some patients, and therefore the effect of amiodarone use may be incorrectly calculated. However, this scenario is felt to be uncommon and therefore its effect on the study findings is expected to be small. Another limitation is that the total amount of amiodarone given to patients cannot be calculated, and therefore a dose effect cannot be evaluated and is beyond the scope of the study. Pharmacy records can be used to calculate the inpatient amiodarone doses, but the dose and duration of amiodarone given to patients after discharge in this clinical situation varies considerably and generally cannot be accurately determined through medical record review. Other limitations of this study are the retrospective nature and the fact that only patients at a single institution were examined. Although the treatment of all patients who develop postoperative atrial fibrillation at our institution follows a general pathway, not all patients are treated by the same providers or in precisely the same manner. This limitation introduces potential confounders such as different selection criteria for amiodarone use among the patients examined. Although the patients who did and did not get amiodarone were well balanced in terms of the most significant risk factors for respiratory complications (age, surgical extent, pulmonary function), the results could have been biased by other unmeasured confounders related to amiodarone use. In addition, including a heterogeneous group of patients in the cohort increases the statistical power of the study but does limit the ability to directly apply the results to a specific patient population, although the analysis did attempt to control for the heterogeneity in the multivariable model. The study is also limited to evaluating the safety of amiodarone but not the efficacy as compared with other treatment strategies, as the use of amiodarone in the majority of patients was after other treatment strategies had failed. Finally, this study does not allow comment on the safety of using amiodarone after a patient has already had a respiratory complication. Caution must be used in these patients who likely already have injured lung parenchyma, as they may be both more susceptible to further injury as well as more likely to show significant clinical deterioration from any further injuries.
In conclusion, atrial fibrillation is a common occurrence after major lung resection. This complication leads to longer hospitalizations and likely increased costs. Amiodarone is very effective at treating atrial fibrillation but is known to cause pulmonary toxicity. Although the safety of using amiodarone in the setting of major lung setting has previously been questioned, amiodarone use in this study was not associated with increased respiratory complications. This is an outstanding series, the largest of amiodarone treated patients for A-Fib [atrial fibrillation] after a major resection. I think you have just scratched the surface on what the real issue is for patients that receive amiodarone. The most important issue is one that you all did not look. One of the main reasons for pulmonary toxicity after amiodarone use is the amount of oxygen that was used during the operation or during the postoperative period. So I would like to know if you have any data in regards to amount and time of oxygen used in the operating room, during the hospitalization, or upon discharge.
DR BERRY: Unfortunately, we do not have that data recorded as part of our prospective data collection and, in general, discerning that data retrospectively can be difficult. Our institutional approach is to use as low an oxygen content as possible intraoperatively. That is a practice pattern that was developed early in the Duke experience with major lung surgery, based on a patient who had induction therapy and then developed ARDS [adult respiratory disease syndrome] postoperatively, thought to be at least partially due to high oxygen content administered during the surgery. Although I cannot comment on exactly how much oxygen is used during the surgery, in general we try to get the anesthesiologists to use as little as possible to keep their saturations at least around 90%. In terms of which patients are discharged with oxygen, we do not have that data.
DR MILLER:
The next question is in reference to late pulmonary toxicity related to amiodarone use. In your series of 112 patients that received amiodarone, you would only predict that six patients could potentially develop pulmonary toxicity, which is a very small number. The main issue that most physicians are concerned about are the long-term toxicity that occurs at 6 to 12 months. Do you have any data at those data points of follow-up?
DR BERRY: No, we do not have that longer term follow-up data, and that is an excellent point. For most people that are on amiodarone and develop pulmonary toxicity, it is a dosedependent problem and it is something that is typically not manifested when they initially start taking amiodarone. However, the impetus for our study was that early study where people did exhibit potential toxicity early after the operation. So, although we cannot comment on whether there is a longer term problem with amiodarone use, at least in the short term it looks like that it is a safe drug to use to treat A-fib.
The third and final question, you said that during the study time period you all did not have an algorithm for treatment of A-fib. From looking at your patients, now, approximately 50% of your patients received amiodarone for their A-fib. What is your algorithm now in regards to treatment of A-fib? DR BERRY: We do not have a specifically defined algorithm, but there is a typical management strategy used in practice on our patient floors. All patients are monitored on telemetry postoperatively, so A-fib is picked up whether it is symptomatic or not symptomatic. The general practice is that a few doses of metoprolol will be tried, usually at least 3 doses of 5 mg intravenous. If the patient continues to have a rapid heart rate, then amiodarone will be the next step. The typical way it is given is as a 150 mg bolus over about an hour, followed by a 24-hour continuous infusion at 1 mg/minute for the first 6 hours and then 0.5 mg for the rest of the 24 hours. Most patients are then started on an oral amiodarone dose. It tends to vary between surgeons whether the patients are just put on a maintenance dose of 200 mg a day or whether they continue to go through an oral loading period.
DR MILLER: I think it will be an excellent follow-up study to this acute toxicity study to review these 112 patients to see what happens to them over the next 6 to 12 months.
DR BERRY: Thank you.
DR KEVIN D. ACCOLA (Orlando, FL): Two quick questions. Most of our pulmonologists are very nervous when patients have a remote history of amiodarone utilization. Had any of the patients in your study that you followed been on amiodarone previously? Second question, and you may have answered this indirectly, but how long do you continue amiodarone? Do you have a set time limit or leave at the discretion of the referring physician? Thank you.
DR BERRY:
In regards to the first question, I think that there were only about 5 patients that previously either had a history of amiodarone or who were receiving amiodarone at the time of surgery. None of those patients were any of the ones who developed respiratory complications.
In terms of the protocol for amiodarone use after the patients are discharged, in general, they are sent home with a prescription for a month's worth of 200 mg per day. The general practice is actually when they come back to see us for their postop visit within about 2 to 3 weeks, if they are in normal sinus rhythm at that time, they are either instructed to stop taking the amiodarone then or they are told to continue taking the amiodarone only until their prescription is completed. DR STEPHEN C. YANG (Baltimore, MD): This was a really great study. I have 2 questions. I noticed you left wedge resections and segmental resections out from your study. Do you have any anecdotal experience regarding those types of patients, especially the ones who have borderline lung function? I think some of them when we do lung biopsies for IPF [idiopathic pulmonary fibrosis] they do have some problems with A-fib afterwards. And then as a corollary to that, when would you not use amiodarone in your patient population?
DR BERRY: It is a good question on the wedge resections and segmental resections. I do not have data for that. The purpose of the study was really to look at the impact when someone has a significant amount of lung resected. Anecdotally, certainly A-fib after a lesser resection is much less common than after these more major lung resections, though elderly patients and patients with poor lung function may have a higher incidence of A-fib. We do not have really any data for that. In general, those patients tend to stay in the hospital so much shorter than the lobectomy patients that I think that they may be discharged before the A-fib would show up on the monitor.
The other agent that was more commonly used as a treatment for atrial fibrillation early in our experience was just a diltiazem drip, and that practice tended to be driven by the cardiologists. That treatment tends to be a little bit more unwieldy for the patients in terms of when to get them off of the drip and how to convert them over to oral agents. So I think amiodarone is easier on the house staff, on the nursing staff, and on the medical decision making.
I'm sorry, can you ask your second question again?
DR YANG: So definitively now, when would you not use amiodarone?
DR BERRY: I do not think there is a specific situation where we definitely do not use amiodarone, though some of our surgeons try to avoid it in patients that have had extrapleural pneumonectomies.
DR JOHN C. ALEXANDER (Pinehurst, NC): Based on the experience in cardiac surgery, why don't you load these people with amiodarone at the time of operation and try to prevent the atrial fibrillation rather than waiting until it occurs?
DR BERRY: That is a good question. I think there may actually be a prospective trial that is looking at that or has looked at it. However, it is not clear if it is worth the expense and the trouble of giving every patient a prophylactic medication when it is only really needed for 18% of the patients. There are also other prophylactic agents and prophylactic regimens that have been studied. We have actually never implemented any of those prophylactic regimens, because it is a little bit unclear what the true benefit of prophylaxis is. Theoretically it would save 2 days of hospital stay for some patients, but it is still unclear how beneficial and how cost effective something like that would be.
